Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
• 3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
• 3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs
    • 4.2.1.2 Increase in CDMO partnerships for scalability
    • 4.2.1.3 Increasing focus on precision/personalized medicine
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
    • 4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Lack of sustainable supply chain
    • 4.2.4.2 Limited scalability of GMP oligonucleotide synthesis
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 KEY CONFERENCES & EVENTS, 2026-2027
• 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.7 INVESTMENT & FUNDING SCENARIO
• 5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET
  • 5.8.1 INTRODUCTION
  • 5.8.2 KEY TARIFF RATES
  • 5.8.3 PRICE IMPACT ANALYSIS
  • 5.8.4 IMPACT ON COUNTRY/REGION
    • 5.8.4.1 US
    • 5.8.4.2 Europe
    • 5.8.4.3 Asia Pacific
  • 5.8.5 IMPACT ON END-USE INDUSTRIES
    • 5.8.5.1 Pharmaceutical & Biotechnology Companies
    • 5.8.5.2 Diagnostic companies
    • 5.8.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Process technologies
      • 6.1.1.1.1 Solid-phase synthesis
      • 6.1.1.1.2 Liquid-phase synthesis
      • 6.1.1.1.3 Enzymatic phase synthesis
    • 6.1.1.2 Purification, analysis, and quality control technologies
      • 6.1.1.2.1 Affinity chromatography
      • 6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Polymerase chain reaction (PCR)
    • 6.1.2.2 Next-generation sequencing (NGS)
    • 6.1.2.3 Microarray technology/hybridization-based assays
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Galnac conjugation/Antibody-oligonucleotide conjugation
    • 6.1.3.2 Lipid nanoparticle (LNP) encapsulation
• 6.2 TECHNOLOGY ROADMAP
• 6.3 FUTURE APPLICATIONS
• 6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
  • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS
  • 6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
  • 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.4.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE

• 9.1 INTRODUCTION
• 9.2 CONTRACT MANUFACTURING
  • 9.2.1 COMMERCIAL STAGE
    • 9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services
  • 9.2.2 CLINICAL STAGE
    • 9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services
• 9.3 CONTRACT DEVELOPMENT
  • 9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH
• 9.4 OTHER SERVICES
  • 9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES

10 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 THERAPEUTIC APPLICATIONS
  • 10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES.
• 10.3 RESEARCH APPLICATIONS
  • 10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH
• 10.4 DIAGNOSTIC APPLICATIONS
  • 10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING

11 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 ANTISENSE OLIGONUCLEOTIDE (ASO)
  • 11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH
• 11.3 SMALL INTERFERING RNA (SIRNA)
  • 11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET.
• 11.4 OTHER OLIGONUCLEOTIDES
  • 11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES

12 OLIGONUCLEOTIDE CDMO MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES
• 12.3 DIAGNOSTIC COMPANIES
  • 12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING
• 12.4 OTHER END USERS

13 OLIGONUCLEOTIDE CDMO MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth.
  • 13.2.2 CANADA
    • 13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada's oligonucleotide CDMO market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany's market growth
  • 13.3.2 UK
    • 13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France's oligonucleotide CDMO market
  • 13.3.4 ITALY
    • 13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy's market growth
  • 13.3.5 SPAIN
    • 13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain's market growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China's market growth
  • 13.4.2 JAPAN
    • 13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan's market growth
  • 13.4.3 INDIA
    • 13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India's oligonucleotide CDMO market
  • 13.4.4 AUSTRALIA
    • 13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia's oligonucleotide CDMO market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market
  • 13.5.2 MEXICO
    • 13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico's oligonucleotide CDMO market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC
    • 13.6.1.1 Saudi Arabia
      • 13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia's oligonucleotide CDMO market
    • 13.6.1.2 UAE
      • 13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE's oligonucleotide CDMO services
    • 13.6.1.3 Rest of GCC Countries
  • 13.6.2 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
• 14.3 REVENUE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
• 14.7 COMPETITIVE SCENARIO
  • 14.7.1 PRODUCT APPROVALS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 14.9 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 BACHEM INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product/Service launches
      • 15.1.1.3.2 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 THERMO FISHER SCIENTIFIC INC.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product/Service launches
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 AGILENT TECHNOLOGIES, INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product/Service launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 WUXI APPTEC
    • 15.1.4.1 Business overview
    • 15.1.4.2 Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths/Right to win
      • 15.1.4.4.2 Strategic choices made
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 MARAVAI LIFESCIENCES
    • 15.1.5.1 Business overview
    • 15.1.5.2 Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
  • 15.1.6 LONZA
    • 15.1.6.1 Business overview
    • 15.1.6.2 Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Deals
      • 15.1.6.3.2 Expansions
  • 15.1.7 EUROFINS SCIENTIFIC
    • 15.1.7.1 Business overview
    • 15.1.7.2 Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Expansions
  • 15.1.8 DANAHER CORPORATION
    • 15.1.8.1 Business overview
    • 15.1.8.2 Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Expansions
      • 15.1.8.3.2 Other Developments
  • 15.1.9 GENSCRIPT
    • 15.1.9.1 Business overview
    • 15.1.9.2 Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Expansions
  • 15.1.10 SYNGENE INTERNATIONAL LIMITED
    • 15.1.10.1 Business overview
    • 15.1.10.2 Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product/Service launches
      • 15.1.10.3.2 Expansions
  • 15.1.11 EUROAPI
    • 15.1.11.1 Business overview
    • 15.1.11.2 Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
      • 15.1.11.3.2 Expansions
  • 15.1.12 AJINOMOTO CO., INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Expansions
      • 15.1.12.3.2 Deals
  • 15.1.13 ST PHARM
    • 15.1.13.1 Business overview
    • 15.1.13.2 Services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Expansions
      • 15.1.13.3.2 Deals
    • 15.1.13.4 MnM view
      • 15.1.13.4.1 Key strengths
      • 15.1.13.4.2 Strategic choices
      • 15.1.13.4.3 Weaknesses and competitive threats
  • 15.1.14 KANEKA CORPORATION
    • 15.1.14.1 Business overview
    • 15.1.14.2 Services offered
  • 15.1.15 POLYPEPTIDE GROUP
    • 15.1.15.1 Business overview
    • 15.1.15.2 Services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Expansions
  • 15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
    • 15.1.16.1 Business overview
    • 15.1.16.2 Services offered
  • 15.1.17 BIOSPRING
    • 15.1.17.1 Business overview
    • 15.1.17.2 Services offered
    • 15.1.17.3 Recent developments
      • 15.1.17.3.1 Service approvals
      • 15.1.17.3.2 Expansions
  • 15.1.18 NIPPON SHOKUBAI CO., LTD.
    • 15.1.18.1 Business overview
    • 15.1.18.2 Services offered
    • 15.1.18.3 Recent developments
      • 15.1.18.3.1 Service launch
      • 15.1.18.3.2 Expansions
  • 15.1.19 LGC BIOSEARCH TECHNOLOGIES
    • 15.1.19.1 Business overview
    • 15.1.19.2 Services offered
    • 15.1.19.3 Recent developments
      • 15.1.19.3.1 Service launch
      • 15.1.19.3.2 Deals
      • 15.1.19.3.3 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 OLIGO FACTORY
  • 15.2.2 CORDEN PHARMA
  • 15.2.3 BIO-SYNTHESIS, INC.
  • 15.2.4 MICROSYNTH
  • 15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC.
  • 15.2.6 HONGENE BIOTECH CORPORATION
  • 15.2.7 SYLENTIS, S.A.
  • 15.2.8 CREATIVE BIOGENE
  • 15.2.9 NITTO AVECIA
  • 15.2.10 NJ BIO, INC.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
  • 16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 16.3 MARKET GROWTH RATE PROJECTIONS
• 16.4 DATA TRIANGULATION
• 16.5 FACTOR ANALYSIS
• 16.6 RESEARCH ASSUMPTIONS
• 16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS

List of Tables

• TABLE 1 OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
• TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES
• TABLE 4 OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM
• TABLE 5 OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-JUNE 2027
• TABLE 6 RECIPROCAL TARIFF RATES ADJUSTED BY US
• TABLE 7 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
• TABLE 8 CLIENTS' READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET
• TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
• TABLE 15 KEY BUYING CRITERIA, BY END USER
• TABLE 16 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 17 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 18 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 19 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 20 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 21 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 22 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 23 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 24 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 25 OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 26 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 27 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 28 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 29 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 30 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 31 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 32 OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 34 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 37 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 38 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
• TABLE 39 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
• TABLE 40 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 41 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 42 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 43 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 44 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
• TABLE 45 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
• TABLE 46 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 48 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 49 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 50 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 51 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 52 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 53 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 54 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 55 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 56 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 57 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 58 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 59 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 60 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 61 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 63 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 66 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 67 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 68 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 69 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 70 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 71 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 73 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 74 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 75 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 76 OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
• TABLE 77 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 78 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 79 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 80 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 81 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
• TABLE 82 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
• TABLE 83 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
• TABLE 84 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 85 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 86 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 87 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 88 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
• TABLE 89 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
• TABLE 90 OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 91 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 92 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 93 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 94 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 95 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 96 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 97 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 98 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 100 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 103 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 104 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 105 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 106 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 107 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 108 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 109 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 110 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 111 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 112 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 115 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 116 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 117 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 118 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 119 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024-2031 (USD MILLION)
• TABLE 120 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 121 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 122 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 123 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 124 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 126 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 127 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 128 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 129 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 130 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 131 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 132 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 133 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 134 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 135 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 136 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 137 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 138 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 139 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 140 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 141 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 142 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 143 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 144 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 145 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 146 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 147 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 148 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 149 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 150 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 151 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 152 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 153 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 154 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 155 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 156 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 157 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 158 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 159 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 160 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 161 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 162 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 163 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 164 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 165 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 166 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 167 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 168 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 169 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 170 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 171 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 173 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 174 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 175 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 176 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 177 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 178 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 179 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 180 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 181 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 182 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 183 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 184 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 185 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 186 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 187 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 188 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 189 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 190 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 191 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 192 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 193 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 194 AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 195 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 196 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 197 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 198 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 199 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 200 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 201 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 202 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 203 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 204 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 205 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 206 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 207 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 208 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 210 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 211 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 212 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 213 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 214 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 215 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 216 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 217 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 218 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 219 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 220 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 221 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 222 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 223 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 224 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 225 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 226 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 227 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 228 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 229 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 230 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 232 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 233 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 234 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 235 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 236 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 237 GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 238 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 239 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 240 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 241 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 242 SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 243 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 244 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 245 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 246 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 247 UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 248 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 249 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 250 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 251 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 252 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 253 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 254 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 255 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 256 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 257 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 258 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 259 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 260 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 261 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 262 AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
• TABLE 263 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 264 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 265 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 266 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
• TABLE 267 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION
• TABLE 268 OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT
• TABLE 269 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT
• TABLE 270 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT
• TABLE 271 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT
• TABLE 272 DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 273 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• TABLE 274 OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
• TABLE 275 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026
• TABLE 276 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 277 BACHEM INC.: COMPANY OVERVIEW
• TABLE 278 BACHEM INC.: SERVICES OFFERED
• TABLE 279 BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
• TABLE 280 BACHEM INC.: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 281 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 282 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
• TABLE 283 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
• TABLE 284 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 285 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 286 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
• TABLE 287 AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
• TABLE 288 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JULY 2026
• TABLE 289 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 290 WUXI APPTEC: COMPANY OVERVIEW
• TABLE 291 WUXI APPTEC: SERVICES OFFERED
• TABLE 292 WUXI APPTEC: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 293 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
• TABLE 294 MARAVAI LIFESCIENCES: SERVICES OFFERED
• TABLE 295 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023-JULY 2026
• TABLE 296 LONZA: COMPANY OVERVIEW
• TABLE 297 LONZA: SERVICES OFFERED
• TABLE 298 LONZA: DEALS, JANUARY 2023-JULY 2026
• TABLE 299 LONZA: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 300 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
• TABLE 301 EUROFINS SCIENTIFIC: SERVICES OFFERED
• TABLE 302 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 304 DANAHER CORPORATION: SERVICES OFFERED
• TABLE 305 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 306 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
• TABLE 307 GENSCRIPT: COMPANY OVERVIEW
• TABLE 308 GENSCRIPT: SERVICES OFFERED
• TABLE 309 GENSCRIPT: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 310 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
• TABLE 311 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
• TABLE 312 SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
• TABLE 313 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 314 EUROAPI: COMPANY OVERVIEW
• TABLE 315 EUROAPI: SERVICES OFFERED
• TABLE 316 EUROAPI: DEALS, JANUARY 2023-JULY 2026
• TABLE 317 EUROAPI: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 318 AJINOMOTO CO., INC.: COMPANY OVERVIEW
• TABLE 319 AJINOMOTO CO., INC.: SERVICES OFFERED
• TABLE 320 AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 321 AJINOMOTO CO., INC.: DEALS, JANUARY 2023-JULY 2026
• TABLE 322 ST PHARM: COMPANY OVERVIEW
• TABLE 323 ST PHARM: SERVICES OFFERED
• TABLE 324 ST PHARM: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 325 ST PHARM: DEALS, JANUARY 2023-JULY 2026
• TABLE 326 KANEKA CORPORATION: COMPANY OVERVIEW
• TABLE 327 KANEKA CORPORATION: SERVICES OFFERED
• TABLE 328 POLYPEPTIDE GROUP: COMPANY OVERVIEW
• TABLE 329 POLYPEPTIDE GROUP: SERVICES OFFERED
• TABLE 330 POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 331 AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW
• TABLE 332 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
• TABLE 333 BIOSPRING: COMPANY OVERVIEW
• TABLE 334 BIOSPRING: SERVICES OFFERED
• TABLE 335 BIOSPRING: SERVICE APPROVALS, JANUARY 2023-JULY 2026
• TABLE 336 BIOSPRING: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 337 NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW
• TABLE 338 NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED
• TABLE 339 NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023-JULY 2026
• TABLE 340 NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 341 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW
• TABLE 342 LGC BIOSEARCH TECHNOLOGIES: SERVICES OFFERED
• TABLE 343 LGC BIOSEARCH TECHNOLOGIES: SERVICE LAUNCH, JANUARY 2023-JULY 2026
• TABLE 344 LGC BIOSEARCH TECHNOLOGIES: DEALS, JANUARY 2023-JULY 2026
• TABLE 345 LGC BIOSEARCH TECHNOLOGIES: EXPANSIONS, JANUARY 2023-JULY 2026
• TABLE 346 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 347 RISK ASSESSMENT

List of Figures

• FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION AND REGIONS CONSIDERED
• FIGURE 2 OLIGONUCLEOTIDE CDMO MARKET: YEARS CONSIDERED
• FIGURE 3 MARKET SCENARIO
• FIGURE 4 GLOBAL OLIGONUCLEOTIDE CDMO MARKET, 2024-2031
• FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
• FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE CDMO MARKET
• FIGURE 7 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE CDMO MARKET, 2026-2031
• FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE CDMO MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
• FIGURE 9 INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE
• FIGURE 10 ANTISENSE OLIGONUCLEOTIDES ACCOUNTED FOR LARGEST SHARE OF OLIGONUCLEOTIDE CDMO MARKET IN NORTH AMERICA IN 2025
• FIGURE 11 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL OLIGONUCLEOTIDE CDMO MARKET DURING FORECAST PERIOD
• FIGURE 12 CONTRACT MANUFACTURING TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 15 VALUE CHAIN ANALYSIS
• FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: ECOSYSTEM ANALYSIS
• FIGURE 17 OLIGONUCLEOTIDE CDMO MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• FIGURE 18 INVESTMENT AND FUNDING SCENARIO, 2023-2026 (USD MILLION)
• FIGURE 19 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
• FIGURE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
• FIGURE 21 KEY BUYING CRITERIA, BY END USER
• FIGURE 22 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
• FIGURE 23 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
• FIGURE 24 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, 2021-2025
• FIGURE 25 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
• FIGURE 26 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2025
• FIGURE 27 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT
• FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2025
• FIGURE 29 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, BY COMPANY
• FIGURE 30 EV/EBITDA OF KEY VENDORS IN CDMO MARKET
• FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE CDMO MARKET
• FIGURE 32 BACHEM INC.: COMPANY SNAPSHOT (2025)
• FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
• FIGURE 34 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
• FIGURE 35 WUXI APPTEC: COMPANY SNAPSHOT (2025)
• FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
• FIGURE 37 LONZA: COMPANY SNAPSHOT (2025)
• FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
• FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
• FIGURE 40 GENSCRIPT: COMPANY SNAPSHOT (2025)
• FIGURE 41 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
• FIGURE 42 EUROAPI: COMPANY SNAPSHOT (2025)
• FIGURE 43 AJINOMOTO CO., INC.: COMPANY SNAPSHOT (2025)
• FIGURE 44 ST PHARM: COMPANY SNAPSHOT (2025)
• FIGURE 45 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
• FIGURE 46 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2025)
• FIGURE 47 NIPPON SHOKUBAI CO., LTD.: COMPANY SNAPSHOT (2025)
• FIGURE 48 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2024)
• FIGURE 49 OLIGONUCLEOTIDE CDMO MARKET: RESEARCH DESIGN
• FIGURE 50 OLIGONUCLEOTIDE CDMO MARKET: BREAKDOWN OF PRIMARIES
• FIGURE 51 OLIGONUCLEOTIDE CDMO MARKET: INSIGHTS FROM PRIMARIES
• FIGURE 52 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
• FIGURE 53 OLIGONUCLEOTIDE CDMO MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
• FIGURE 54 ILLUSTRATIVE EXAMPLE OF AGILENT TECHNOLOGIES, INC.: REVENUE ANALYSIS (2025)
• FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
• FIGURE 56 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS
• FIGURE 57 OLIGONUCLEOTIDE CDMO MARKET: DATA TRIANGULATION